Novo Nordisk acquires Cardior for 1 billion euros to accelerate its layout in the cardiovascular field
Ty奇葩罗牛山831
发表于 2024-3-26 12:50:58
1156
0
0
On Monday local time, Danish pharmaceutical giant Novo Nordisk announced that it will acquire Cardio Pharmaceuticals for 1.03 billion euros, and the two companies have reached a related acquisition agreement. At present, Novo Nordisk is expanding beyond the market of diabetes and weight loss, and accelerating the layout of its product lines for cardiovascular diseases.
In recent years, Novo Nordisk has achieved great success because of its star weight loss drugs and diabetes treatment drugs (Ozempic and Wegovy). These drugs are not only very effective in regulating blood sugar and helping patients lose weight, but also produce additional health benefits, such as reducing the risk of stroke and heart disease, and slowing down the progress of kidney disease.
Based on these findings, Novo Nordisk announced this month that the company will invest significant resources in the field of cardiovascular disease to establish a competitive track.
David Moore, Executive Vice President of Enterprise Development at Novo Nordisk, stated that the company will seek to fully develop its first independent cardiovascular disease drug, Ziltivekimab. It is reported that the drug is in the phase III research and development stage and is used to treat atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
Novo Nordisk issued a statement on Monday stating, "The acquisition of Cardior is an important step for Novo Nordisk to expand its business scope and influence in the field of cardiovascular disease."
Cardior is a German biopharmaceutical company founded in 2016, focusing on the development of non coding RNA (ncRNA) based heart failure treatments and preventive drugs. NcRNAs include microRNAs and lncRNAs, which regulate signaling pathways within molecular cells, leading to myocardial remodeling and heart failure.
It is reported that the lead compound CDR132L of Cardior can improve heart function, prevent and partially reverse the disease progression of heart failure patients, and is currently in the phase II clinical development stage for treating heart failure. Novo Nordisk plans to launch follow-up experiments after the acquisition.
The transaction is expected to be completed in the second quarter of 2024. This funding will come from financial reserves, so it will not affect Novo Nordisk's profit guidance for 2024 or ongoing stock repurchases.
Martin Holst Lange, Executive Vice President of Development at Novo Nordisk, said, "The scientific work carried out by the Cardior team has left a deep impression on us, especially the CDR132L, which has a unique mode of action and may become a first-class treatment for cardiovascular disease, preventing or partially reversing the disease progression of heart failure patients."
Dr. Claudia Ulbrich, CEO and co-founder of Cardior, said, "This acquisition reflects the transformative potential of CDR132L as a treatment for cardiovascular disease. With its profound clinical and business knowledge, as well as its resources, Novo Nordisk can accelerate our later development plans, including through larger scale registration research, making it an ideal partner. We look forward to CDR132L's early market approval."
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- SAP's cloud business revenue in the first quarter was 3.93 billion euros, a year-on-year increase of 24%
- Global Layout "Low Altitude" Takeoff, Express Delivery Leader Builds Second Growth Curve
- Amazon Cloud Services Layout in Europe: Planned to spend $8.4 billion to build infrastructure in Germany
- Google invests 1 billion euros in Finnish data centers to drive the development of artificial intelligence
- Google plans to invest 1 billion euros to expand Finland's data center park
- Amazon is reportedly in talks with Italy to invest billions of euros in cloud plans
- Microsoft is reportedly close to reaching a multi million euro deal with cloud computing industry organizations to end EU antitrust complaints
- Tesla will invest $500 million to lay out a supercharged network
- Ferrari's first electric car is priced at least 500000 euros, and the second electric vehicle model is under development
- Investment experts firmly believe that Nvidia's narrative prospects: short-term fluctuations will not affect long-term layout
-
理想自動車官博によると、2024年6月、理想自動車が新車47774台を納入し、前年同期比46.7%増となった。2024年第2四半期に108,581台が納入され、前年同期比25.5%増加した。2024年6月30日現在、理想自動車の累計納入台 ...
- 寒郁轩良
- 5 小时前
- 支持
- 反对
- 回复
- 收藏
-
【スタンダード500指数が今年31回の高値を迎えるにあたり、ゴールドマン・サックスは今こそ「ブレーキを踏む」ことができると警告した!】今年、大手科学技術株がスタンダード500指数の強力な反発を後押しし、一連 ...
- 愿为素心人
- 前天 13:02
- 支持
- 反对
- 回复
- 收藏
-
最新の財報は市場予想を下回り、ナイキは急落した。 現地時間6月28日金曜日、米株3大株価指数が集団で下落した。終値まで、ダウ平均は0.12%、ナ指は0.71%、スタンダード500指数は0.41%下落した。 経済データについ ...
- hecgdge4
- 前天 09:48
- 支持
- 反对
- 回复
- 收藏
-
6月30日、Kindle中国電子書店はダウンロードサービスを停止し、ホット検索に突入した。 アマゾンの中国公式サイトによると、2024年6月30日からKindle中国電子書店はクラウドダウンロードサービスを停止し、その後ダ ...
- 什么大师特
- 13 小时前
- 支持
- 反对
- 回复
- 收藏